Gilead More than Doubles Original Courses Expectation for Remdesivir to Fight Covid
Gilead announced today (6/22) that its expectation for supply of remdesivir to fight Covid increased from 1 million to exceed 2 million by the end of 2020. Remdesivir is on the forefront of fighting the pandemic, helping shorten the length of hospital recovery times...
Dexamethasone and COVID-19: The Breakthrough Steroid Saving Severely Ill Patients
Dexamethasone, a cheap and widely used steroid used to reduce inflammation for patients afflicted with arthritis, asthma, some skin conditions, and more, has been recognized as a breakthrough treatment from severely ill COVID-19 patients. When in use, it has shown to...
Johnson & Johnson to Begin Human Trials of Covid Vaccine in July
Johnson & Johnson announced today (6/10) that they will be initiating human trials in the second half of July for the Covid vaccine. The trials are expected to last over the course of two months in both the United States as well as Belgium, and will be...
WHO Prequalifies Rituximab Biosimilar for Cancer Treatment
The World Health Organization (WHO) has prequalified a biosimilar of version of rituximab, which is used to treat certain cancers and autoimmune diseases, created by Celltrion. This drug therapy is the second to achieve prequalification status under the...
FDA Releases MyStudies App for Patient Informed Consent
The FDA released the app FDA MyStudies, which can be found in app stores as COVID MyStudies, for patients to provide informed consent for traditional clinical trials, real-world trials, observational studies, and registries. The app is free, as...
The United States Grants $628 Million Contract with Emergent for Covid
Due to the Covid pandemic, The Department of Health and Human Services granted Emergent BioSolutions a $628 million contract under the Biomedical Advanced Research and Development Authority (BARDA), a U.S. federal agency that funds disease-fighting technology in...
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com